430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
https://www.bms.com
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 32,200
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Giovanni Caforio M.D. | Chairman & CEO | 5.82M | N/A | 1965 |
Mr. David V. Elkins | Exec. VP & CFO | 3.18M | 1.3M | 1968 |
Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel | 2.73M | N/A | 1961 |
Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer | 2.61M | N/A | 1971 |
Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. | 3.21M | 1.45M | 1965 |
Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer | N/A | N/A | 1973 |
Mr. Timothy Power | VP & Head of Investor Relations | N/A | N/A | N/A |
Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer | N/A | N/A | N/A |
Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
Mr. Jitendra Tyagi | Head of US Drug Makers - India | N/A | N/A | N/A |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company’s ISS governance QualityScore as of 28 January 2023 is 2. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 3; Compensation: 1.